Suven Life Sciences is up 5.9% at Rs. 248.85 on NSE this morning, with total traded volume of over 11 lakh shares, as against 2 week average daily traded quantity of less than 5 lakh shares on NSE. Even on BSE, volumes of 2.6 lakh shares are more than double the average volumes of 1.2 lakh shares. Share price has retreated from day’s high of 251.85.

Company has secured 4 product patents for its New Chemical Entities (NCEs) in China, Mexico and South Africa. While patents in China and South Africa, developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders, are valid until 2030, the patent secured in Mexico is being developed as therapeutic agents for major depressive disorder (MDD) and is valid through 2030. Just last month, in June 2015, company had won 6 product patents in Israel, Japan, US, South Africa and Macau.

With these new patents, Suven has a total of 16 granted patents from China, 19 from Mexico and 22 from South Africa and all these granted patents are exclusive intellectual property of the company which are achieved solely through internal discovery research efforts.

Suven Life Science, a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, reported revenue of Rs. 520 crore in FY15 and earned PAT of Rs. 109 crore, leading to EPS of Rs. 9. Its current market cap stands at Rs. 3,150 crore and promoters own 59.44%.